

REFERENCES

**Order** YOUR AGREEMENT  
**Offer :** DR17-01069 Rev 2  
**Received Rouen** 10/03/17  
**Requested by:** Mr Karem Eladwey  
**ClientID:** GENTO ANTI BACTERIAL BAR SOAP 29350  
**Description:** GENCODE : 6282307201760  
**Nature:** Cosmetic product  
**Comments:**

SAUDI INDUSTRIAL DETERGENT CO.  
P.O. Box: 2571,  
  
Damman  
Saudi Arabia

Rouen 07 / 07 / 2017

REPORT  
**RN17-05835.001 B** Page 1 / 1

Parameters	Units	Results
<b>Human repeat insult patch test (2)</b> (Méthode sous traitement)	%	enclosed

Results validated electronically by **Marine CHAPELLE**  
Responsible Projet



this validation is an electronical signature realised in conformity with requirements of ISO 17025

- (1) Assays subcontracted in a SGS laboratory
- (2) Assays subcontracted in a partner laboratory
- (3) Uncertainty with k=2 without other described note in the test report directly.

Abbreviations ME or MO described within the field "parameters" of this report mean "Internal method" (adapting from the reference text if described hereinafter).

This document is issued by the Company subject to its General Conditions of Service available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>.  
Attention is drawn to the limitation of liability, indemnification, jurisdiction and to the use of SGS and COFRAC brand-names issues defined therein.  
Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.  
Unless otherwise stated the results shown in this test report refer only to the sample(s) tested and such sample(s) are retained for 60 days only (indeed less depending on kind of sample(s)) or more than 60 days according to particular client's request.  
WARNING: The sample(s) to which the findings recorded herein (the "Findings") relate was(were) drawn and / or provided by the Client or by a third party acting at the Client's direction. The Findings constitute no warranty of the sample's representativeness of any goods and strictly relate to the sample(s). The Company accepts no liability with regard to the origin or source from which the sample(s) is/are said to be extracted.

**SENSITIZING POTENTIAL STUDY OF A PRODUCT  
ACCORDING TO MARZULLI-MAIBACH METHOD  
HRIPT - FINAL CLINICAL SECURITY TEST**

**REPORT**

STUDY REFERENCE	<b>CT-072</b>
PRODUCT	<b>«Gento Antibacterial Bar Soap (RN17-05835.001)»</b>
NUMBER OF SUBJECTS	<b>50</b>
PROMOTER	<b>SIDCO (Saudi Industrial Detergents Company)</b>
SPONSOR	<b>SGS MULTILAB</b>
MONITOR	<b>LISKIN IMMEUBLE FONTENAY AFFAIRES 91, Rue Boucicaut 92260 FONTENAY-AUX-ROSES ☎ : 33 (0)9 70 90 65 17</b>
INVESTIGATOR	<b>Dr Marlena Nowakowska, dermatologist</b>

**CONFIDENTIAL DOCUMENT - PROMOTER PROPERTY**

Document including 22 pages

The following results concern only the samples subjected to LISKIN and as they are defined in this document  
The reproduction of this report is authorized only in the photographic facsimiled integral form

## TABLE OF CONTENT

<b>STUDY SUMMARY</b>	<b>2</b>
<b>1. QUALITY POLICY</b>	<b>3</b>
<b>2. CONFORMITY CERTIFICATE</b>	<b>3</b>
<b>3. METHOD</b>	<b>4</b>
<b>3.1. STUDY PRODUCT</b>	<b>4</b>
<b>3.2. CLINICAL METHODS</b>	<b>4</b>
3.2.1. Aim of the study	4
3.2.2. Experimental design	4
3.2.3. Study subjects	4
<b>3.3. MATERIAL</b>	<b>5</b>
<b>4. PRODUCT APPLICATION</b>	<b>6</b>
<b>5. STUDY SCHEDULE</b>	<b>6</b>
<b>6. ASSESSMENT CRITERIA</b>	<b>7</b>
<b>6.1. CLINICAL CRITERIA REGARDING THE IRRITATING POTENTIAL (INDUCTION PHASE)</b>	<b>7</b>
<b>6.2. CLINICAL CRITERIA REGARDING THE SENSITIZING POTENTIAL (CHALLENGE PHASE)</b>	<b>8</b>
<b>6.3. ASSESSMENT METHOD</b>	<b>8</b>
6.3.1. Irritating potential - Induction Phase	8
6.3.2. Sensitizing potential - Challenge Phase	8
<b>6.4. PREMATURE STUDY TERMINATION</b>	<b>9</b>
<b>6.5. PROTOCOL'S AMENDMENT</b>	<b>9</b>
<b>7. RESULTS</b>	<b>9</b>
<b>7.1. IRRITATING POTENTIAL: INDUCTION PHASE</b>	<b>9</b>
<b>7.2. SENSITIZING POTENTIAL: CHALLENGE PHASE</b>	<b>10</b>
<b>8. CONCLUSION</b>	<b>10</b>
<b>APPENDICES</b>	<b>11</b>

## STUDY SUMMARY

**TITLE :** SENSITIZING POTENTIAL STUDY OF A PRODUCT «Gento Antibacterial Bar Soap (RN17-05835.001)» ACCORDING TO MARZULLI-MAIBACH METHOD, ON 50 SUBJECTS DURING 6 WEEKS - FINAL CLINICAL SECURITY TEST

**STUDY REFERENCE :** CT-072

**PRODUCT :** Gento Antibacterial Bar Soap (RN17-05835.001)

**STUDY IMPLEMENTATION:** The study was carried out and all test values recorded by the Clinical Unit PROCOS, localized in Poland; ul. Słowackiego 27/33 lok. 33/34; 01-592 Warsaw.

**INVESTIGATOR :** Dr Marlena NOWAKOWSKA

**PROTOCOL :** CLINICAL EVALUATION OF THE SENSITIZING POTENTIAL OF A PRODUCT ACCORDING TO MARZULLI-MAIBACH METHOD.

**AIM OF THE STUDY :** To evaluate the irritating and sensitizing potential of a product (tested 5% diluted with water) under dermatological control and under the conditions defined by study's sponsor.

**SUBJECTS :** 50 healthy volunteers with sensitive skin corresponding to the inclusion and non-inclusion criteria defined by LISKIN.

**STUDY SCHEDULE :** May 08th to June 16th, 2017

**EXPERIMENTAL DESIGN :** simple blind and monocentric study.

### MAIN TOLERANCE PARAMETERS :

- Irritation potential (Induction Phase)

Erythema, oedema, desquamation, vesicles rated from 0 to 3 by the dermatologist

- Sensitizing potential (Challenge Phase)

Reaction rated from 0 to 3 by the dermatologist according to ICDRG (International Contact Dermatitis Research Group)

### RESULTS :

PRODUCT CA NAME	Irritation potential	Sensitizing potential
Gento Antibacterial Bar Soap (RN17-05835.001)	Mean rate of 0,000 = <b>non-irritating</b>	No allergic reaction

### CONCLUSION :

**Under these study conditions, the product «Gento Antibacterial Bar Soap (RN17-05835.001)» can be considered non-irritating and non-sensitizing.**

## 1. QUALITY POLICY

The study described has been conducted according to the TCSF-AFFSAPS recommendations (December 2008 final version) and the Good Clinical Practice Guidelines from FDA (FR of 8/08/1978 Part V - Decree n°77N-0278), EEC (Directives n°91/507 and III 3976/88 of 11/07/1990) and to the Ministry of Health of the French Republic.

The study has been conducted according to Standard Operating Procedures and to the study protocol defined by the sponsor. Every study events recorded during the study is reported.

The first evaluation of sensitization risks for all ingredients depends on the responsibility of the tested product manufacturer.

Controls on data veracity and conformity with the protocol, have been performed and confirmed by persons participating to the study (APPENDIX I).

This report is a translation of an original report written in French.

## 2. CONFORMITY CERTIFICATE

I am aware that the study CT-072 has been conducted according to the «**Quality Assurance**» described before.

**There was no event which may have affected the quality or integrity of the data.**



---

Mme Charlotte OEHMICHEN  
Technical Director

June 27<sup>th</sup>, 2017

---

date

### 3. METHOD

#### 3.1. STUDY PRODUCT

The product supplied by "SGS MULTILAB", has the following characteristics :

Product name	Product presentation	Study ref	SGS N°
Gento Antibacterial Bar Soap (RN17-05835.001)	yellow soap bar	CA	RN17-05835.001

The product was delivered on March 20th, 2017.

A sample of the tested product is stored at ambient T°C and safe from the light, in the buildings of LISKIN, for 3 months after the end of the study. Passed this time and except contrary opinion of the promoter the product is destroyed.

#### 3.2. CLINICAL METHODS

##### 3.2.1. Aim of the study

To assess irritation potential and the sensitizing potential of a product under dermatological control and according to Marzulli-Maibach method.

##### 3.2.2. Experimental design

This was an open study.

##### 3.2.3. Study subjects

###### Inclusion criteria

- Healthy volunteer of Caucasian origin,
- Age between 18 and 70,
- Phototype II, III or IV,
- Sensitive skin,
- Subjects having given their informed, written consent,
- Cooperative subjects, aware of the necessity and duration of controls so that perfect adhesion to the protocol established by LISKIN could have been expected.

###### Non-inclusion criteria

- Pregnancy or nursing women,
- Sun exposure or UV exposure 15 days before study and/or photopatchtests from less than 2 months,
- Hyper irritable skin,
- Known allergies or sensitivities to cosmetics product and Elastoplast,
- skin pathology on the test zones, Scars, beauty spots, freckle or any abnormality, on the back,
- Subjects afflicted with serious or progressive diseases,
- Volunteers undergoing a topical or systemic treatment: anti-inflammatories, antihistamines, immuno-suppressors, corticoids and retinoids.

## Inclusion

50 healthy volunteers have been selected according to the inclusion and the non-inclusion criteria, and 50 subjects completed the study. The table below presents the informations concerning all the volunteers included.

	Non included	Included	Drop out	Untraceable
Number of subjects	0	50	0	0

## Subjects characteristics

The summary table below presents a synthesis of the observations concerning exclusively the volunteers taken into account for data analysis.

Number of subjects	Sex	Age (mean±SEM)	Phototype (subject number)	Medical or surgical events and medical treatments	
				Before study	During the study
50	39 F 11 M	39 ± 2	II : 50 III : 0 IV : 0	cf. Table in APPENDIX II	

### 3.3. MATERIAL

The semi-occlusive patches used are “Band of Webri®” (4cm<sup>2</sup>) ensuring a semi occlusion.

### 4. PRODUCT APPLICATION

Application area	Scapular zones: homolateral (induction zone) and controlateral (challenge zone)
Quantity and Concentration applied	50 µl 5% diluted with water
Frequency	Induction Phase: 3 times a week during 48 hours Challenge Phase: once during 48 hours
Contact time	Induction Phase: 3 weeks Rest Phase: 2 weeks Challenge Phase: 1 week
Application conditions	Before any application, the skin was cleaned and dried. The product «Gento Antibacterial Bar Soap (RN17-05835.001)» was applied under a semi-occlusive patch (filter paper) on the subject's back. A patch containing no product was applied under the same conditions to serve as a non-treated control. During all Induction Phase, the homolateral zone was not wet. The subjects took a shower on sunday, after patch removal and paid attention not to put any detergent product on all tested zones. During all Challenge Phase, no washing and no product application took place on controlateral zone.

## 5. STUDY SCHEDULE

The study was carried out according to the following diagram:

### Induction Phase - 3 weeks (W1, W2, W3)

W1:

Day of the week	Mo	Tu	We	Th	Fr	Sa	Su
Study day	D1	D2	D3	D4	D5	D6	D7
Product application	↓		↓		↓		
Readings			R		R		

W2:

Day of the week	Mo	Tu	We	Th	Fr	Sa	Su
Study day	D8	D9	D10	D11	D12	D13	D14
Product application	↓		↓		↓		
Readings	R		R		R		

W3:

Day of the week	Mo	Tu	We	Th	Fr	Sa	Su
Study day	D15	D16	D17	D18	D19	D20	D21
Product application	↓		↓		↓		
Readings	R		R		R		

After having removed the last patch of the induction phase at home, it was asked to the subjects, to come at the clinical unit D22 if a new sign appeared (or deterioration of an existing sign D19).

### Rest Phase - 2 weeks (W4, W5)

W4:

Day of the week	Mo	Tu	We	Th	Fr	Sa	Su
Study day	D22	D23	D24	D25	D26	D27	D28

W5:

Day of the week	Mo	Tu	We	Th	Fr	Sa	Su
Study day	D29	D30	D31	D32	D33	D34	D35

### Challenge Phase - 1 week (W6)

W6:

Day of the week	Mo	Tu	We	Th	Fr
Study day	D36	D37	D38	D39	D40
Product application	↓				
Readings			R		R

## 6. ASSESSMENT CRITERIA

### 6.1. CLINICAL CRITERIA REGARDING THE IRRITATING POTENTIAL (INDUCTION PHASE)

After each application, the patch is removed and the clinical examination is performed by the investigator 30 minutes later in order to eliminate the pressure and the occlusion effects.

The result of examination is zero if the skin looks normal.

The clinical examination is made on the back using the following criteria and scale:

Score	Cotation	CRITERIA : description			
		ERYTHEMA	EDEMA	DRYNESS	VESICLES
0	Absent	Normal aspect	Normal aspect	Normal aspect	Normal aspect
0.5	Doubtful	Barely perceptible: quite pink coloration of one part of the tested area			
1	Slight	Discreet pink coloration of the whole tested area or rather visible on part of the tested area	More palpable than visible oedema	Discreet thin desquamation, tarnished aspect	More palpable than visible vesicles
2	Marked	Marked erythema covering the whole tested area	Visible oedema	Visible desquamation, flaky aspect.	Visible vesicles
3	Important	Severe erythema covering the whole tested area or erythema diffusing beyond the tested area	Oedema diffusing beyond the tested area	Important desquamation, cracking	Vesicles diffusing beyond the tested area or blisters.

### 6.2. CLINICAL CRITERIA REGARDING THE SENSITIZING POTENTIAL (CHALLENGE PHASE)

The allergic reactions are evaluated according to the following scale:

Criterion	Quotation ICDRG (*)	Score noted in all tables
No reaction	0	0
Doubtful reaction	?	?
Erythema and oedema	+	1
Erythema, oedema and vesicles	++	2
Severe reaction with blisters	+++	3

(\*) - International Contact Dermatitis Research Group

### 6.3. ASSESSMENT METHOD

#### 6.3.1. Irritating potential - Induction Phase

After the 8 readings of the induction phase, the average score of every volunteer was calculated by adding the scores obtained for each of the readings and by dividing this sum by the actual number of readings made at the clinical unit (a reading was not taken into account if there was reaction of the control or global irritation).

The irritating potential of the product will be estimated during the Induction Phase, by calculating the mean of the reactions observed.

The irritating potential (IRR) of the product is determined according to the following formula:

$$\text{Average score} = \frac{[(\sum \text{scores D1...D19} / \text{nb of readings}) \text{vol1} + \dots + (\sum \text{scores D1...D19} / \text{nb of readings}) \text{volN}]}{\text{nb of volunteers (N)}}$$

Average score (IRR)	Irritating Potential
Score < 0,080	Non-irritating
0,080 ≤ score < 0,160	Very slightly irritating
0,160 ≤ score < 0,560	Slightly irritating
0,560 ≤ score < 1,000	Moderately irritating
1,000 ≤ score < 1,600	Strongly irritating
1,600 ≤ score	Very strongly irritating

#### 6.3.2. Sensitizing potential - Challenge Phase

The possible allergic reaction, during the Induction or Challenge Phase, will be rated from 0 to 3 according to ICDRG (International Contact Dermatitis Research Group). During the Challenge Phase, the reading will take place 30 minutes after patch-tests removal and 48 hours later.

The sensitizing potential of the product will be assessed by the reading D38 and D40 (Challenge Phase) as a function of the following criteria: reaction ++ (2) or +++ (3).

The presence of only one case of active sensitizing (**upper or equal score in ++ (2)**) on controlateral side leads to the conclusion "Potentially sensitive product".

### 6.4. PREMATURE STUDY TERMINATION

The subjects have the right to leave the study at any time whatever the reason.

The premature study termination can be for multiple reasons:

- non-compliance with the visits schedule by the subject,
- adverse events (including intercurrent diseases),
- protocol non-adherence/departures from protocol,
- Withdrawal of subject's consent.

The doctor investigator can interrupt the essay, either on certain subjects, or on the the whole panel, if the product induces important or abnormal cutaneous reactions, or if he considers that the continuation of the essay can damage health of one or several concerned subjects

## 6.5. PROTOCOL AMENDMENT

None

## 7. RESULTS

### 7.1. IRRITATING POTENTIAL: INDUCTION PHASE

The TABLE OF READINGS regarding the Induction Phase is presented in APPENDIX III.

These reading made 30 min. after having removed the patch-tests showed the following results:

Produit CA	J3	J5	J8	J10	J12	J15	J17	J19	Conclusion
Gento Antibacterial Bar Soap (RN17- 05835.001)	Results - number of subjects								<b>non irritant</b> (IRR = 0,000)
	T+ : 0 0 : 50	T+ : 0 0 : 50	T+ : 0 0 : 50	T+ : 0 0 : 50	T+ : 0 0 : 50	T+ : 0 0 : 50	T+ : 0 0 : 50	T+ : 0 0 : 50	
	Results - Percentage								
	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	T+ : 0% 0 : 100%	
C+ = Positive control			IRR = global irritation			MV = missing value			

**Under these study conditions, the product «Gento Antibacterial Bar Soap (RN17-05835.001)» showed a score lower than 0.080, so it can be considered non-irritating.**

## 7.2. SENSITIZING POTENTIAL: CHALLENGE PHASE

The TABLE OF READING regarding the Challenge Phase is presented in APPENDIX IV.

These reading made 30 minutes and 48 hours after having removed the patch-tests showed the following results:

Product Code : CA	Zones	Score	Day of the reading				Global result
			D38		D40		
			n	%	n	%	
Gento Antibacterial Bar Soap (RN17- 05835.001)	Homolateral zone readings	T+ :	0	0	0	0	non-sensitizing
		0 :	50	100	50	100	
		? :	0	0	0	0	
		1 :	0	0	0	0	
		2 :	0	0	0	0	
		3 :	0	0	0	0	
	Controlateral Zone readings	T+ :	0	0	0	0	
		0 :	50	100	50	100	
		? :	0	0	0	0	
		1 :	0	0	0	0	
		2 :	0	0	0	0	
		3 :	0	0	0	0	

CA = Gento Antibacterial Bar Soap (RN17-05835.001)

T+ = Positive control

VM = missing value

n = number of subjects

% = % of subjects

Under these study conditions, no reaction ++ (2) nor +++ (3) were observed, so the product «Gento Antibacterial Bar Soap (RN17-05835.001)» can be considered non-sensitizing.

## 8. CONCLUSION

Under these study conditions, the product «Gento Antibacterial Bar Soap (RN17-05835.001)» can be considered non-irritating and non-sensitizing.

## APPENDICES

APPENDIX I:	13
RESULTS AUTHENTICATION SHEET	
APPENDIX II:	15
SUBJECTS CHARACTERISTICS	
APPENDIX III:	18
TABLE OF READING - INDUCTION PHASE	
APPENDIX IV:	21
TABLE OF READING - CHALLENGE PHASE	

## **APPENDIX I**

### **RESULTS AUTHENTICATION SHEET**

**ORYGINAŁ**

**KARTA AUTENTYCZNOŚCI REZULTATÓW**  
**FICHE D'AUTHENTIFICATION DES RESULTATS**  
**AUTHENTICATION PAGE**

**CT-072**

**RIPT - Human Repeated Insult Patch Test**

Według posiadanych przeze mnie informacji, badanie było przeprowadzone zgodnie PROTOKOŁEM oraz KARTĄ PARAMETRÓW TESTU.

*A ma connaissance l'étude a été conduite en accord avec le PROTOCOLE et la FICHE DES PARAMETRES D'ETUDE.*


*To my knowledge the study has been conducted according to the PROTOCOL and STUDY PARAMETERS PAGE.*

**Mgr inż. Barbara WAŁEJKO**

Odpowiedzialna za badania

*Responsable d'unité*

*Unit Manager*



podpis / signature

2017-06-16


data / date

**Dr Marlena NOWAKOWSKA**

Lekarz dermatolog

*Médecin dermatologue*

*Dermatologist*



podpis / signature

2017-06-16


data / date

**Mgr Magdalena KUREK**

Odpowiedzialna za jakość

*Responsable Qualité*

*Quality Manager*



podpis / signature

2017-06-16

data / date

**Barbara KRÓL**

Asystentka

*Assistante Technique*

*Technical Assistant*



podpis / signature

2017-06-16

data / date

## **APPENDIX II**

### **SUBJECTS CHARACTERISTICS**

## SUBJECTS CHARACTERISTICS

Subject number	Subject code	Age	Sex	Photo-type	Skin type (Normal or Sensitive)	Medical or surgical events and medical treatments	
			F or M			before the study	during the study
1	SLADA	57	F	II	S	-	-
2	BIEAL	58	F	II	S	-	-
3	NOWBE	33	F	II	S	-	-
4	WAJPI	38	M	II	S	-	-
5	MORKR	27	F	II	S	-	-
6	NATJA	33	F	II	S	-	-
7	SZEAL	57	F	II	S	-	-
8	MIKEW	23	F	II	S	-	-
9	ANIJO	35	F	II	S	-	-
10	KRZAN	48	M	II	S	-	-
11	SIEEL	61	F	II	S	-	-
12	ROWTE	20	M	II	S	-	-
13	KOWIR	27	F	II	S	-	-
14	CALAL	50	F	II	S	-	-
15	SAJAD	29	F	II	S	-	-
16	KOLTE	39	F	II	S	-	-
17	JECBA	50	F	II	S	-	-
18	TALEM	36	F	II	S	-	-
19	POGMI	45	M	II	S	-	-
20	CZAMA	44	F	II	S	-	-
21	KAZWI	42	F	II	S	-	-
22	KORIZ	57	F	II	S	-	-
23	PIEBA	34	F	II	S	-	-
24	CHYCZ	53	F	II	S	-	-
25	WIEMO	32	F	II	S	-	-
26	LUKDO	30	F	II	S	-	-
27	KONDO	22	F	II	S	-	-
28	LYSAG	25	F	II	S	-	-
29	ZULJA	27	M	II	S	-	-
30	RZEST	34	M	II	S	-	-

UN = untraceable

SUBJECTS CHARACTERISTICS - (continuation)

Subject number	Subject code	Age	Sex	Photo-type	Skin type (Normal or Sensitive)	Medical or surgical events and medical treatments	
			F or M			before the study	during the study
31	MILHA	27	F	II	S	-	-
32	POLWI	40	F	II	S	-	-
33	JARAN	25	F	II	S	-	-
34	KRUJA	49	F	II	S	-	-
35	NOWLU	53	F	II	S	-	-
36	FALKO	27	M	II	S	-	-
37	MAZBE	27	F	II	S	-	-
38	WIEEW	44	F	II	S	-	-
39	WECJA	61	M	II	S	-	-
40	SZLAN	36	F	II	S	-	-
41	ZANTE	31	F	II	S	-	-
42	JASMA	28	F	II	S	-	-
43	SKIBA	38	F	II	S	-	-
44	GLOMI	54	M	II	S	-	-
45	SWIEW	37	F	II	S	-	-
46	BORTE	41	F	II	S	-	-
47	MECMA	25	M	II	S	-	-
48	ZYCDA	53	M	II	S	-	-
49	BRZJO	55	F	II	S	-	-
50	SKRAL	41	F	II	S	-	-

UN = untraceable

## **APPENDIX III**

### **TABLE OF READING INDUCTION PHASE**

TABLE OF READING - Induction Phase

Subject number	D3		D5		D8		D10		D12		D15		D17		D19	
	C	CA	C	CA	C	CA	C	CA	C	CA	C	CA	C	CA	C	CA
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

UN = untraceable

C = control

CA = Gento Antibacterial Bar Soap (RN17-05835.001)

TABLE OF READING - Induction Phase (continuation)

Subject number	D3		D5		D8		D10		D12		D15		D17		D19	
	C	CA	C	CA	C	CA	C	CA	C	CA	C	CA	C	CA	C	CA
31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

UN = untraceable

C = control

CA = Gento Antibacterial Bar Soap (RN17-05835.001)

## **APPENDIX IV**

### **TABLE OF READING CHALLENGE PHASE**

TABLE OF READING - Challenge Phase

Subject number	D38 Homolateral zone		D38 Controlateral zone		D40 Homolateral zone		D40 Controlateral zone	
	C	CA	C	CA	C	CA	C	CA
1	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0

UN = untraceable

C = control

CA = Gento Antibacterial Bar Soap (RN17-05835.001)

TABLE OF READING - Challenge Phase (continuation)

Subject number	D38 Homolateral zone		D38 Controlateral zone		D40 Homolateral zone		D40 Controlateral zone	
	C	CA	C	CA	C	CA	C	CA
31	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0

UN = untraceable

C = control

CA = Gento Antibacterial Bar Soap (RN17-05835.001)